Roivant Sciences (ROIV) News Today $17.26 +0.15 (+0.88%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$17.26 0.00 (0.00%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ROIV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 118,418 Shares of Stock3 hours ago | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 318,282 Shares3 hours ago | marketbeat.comEric Venker Sells 414,683 Shares of Roivant Sciences (NASDAQ:ROIV) Stock3 hours ago | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 118,418 SharesOctober 18 at 5:43 AM | insidertrades.comEric Venker Sells 20,727 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 15, 2025 | marketbeat.comEric Venker Sells 104,940 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 15, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High - Still a Buy?October 15, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Sells $336,813.75 in StockOctober 15, 2025 | insidertrades.comGoldman Sachs Sticks to Their Buy Rating for Roivant Sciences (ROIV)October 10, 2025 | theglobeandmail.comEric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 171,396 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 355,161 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | insidertrades.comWeiss Ratings Reaffirms "Sell (D+)" Rating for Roivant Sciences (NASDAQ:ROIV)October 9, 2025 | marketbeat.comValeo Financial Advisors LLC Buys Shares of 101,576 Roivant Sciences Ltd. $ROIVOctober 8, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Sets New 12-Month High - Should You Buy?October 7, 2025 | marketbeat.comWhy Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst UpgradesOctober 4, 2025 | finance.yahoo.comElevate Capital Advisors LLC Sells 61,368 Shares of Roivant Sciences Ltd. $ROIVOctober 4, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Hits New 52-Week High - Here's What HappenedOctober 1, 2025 | marketbeat.comLVW Advisors LLC Makes New $199,000 Investment in Roivant Sciences Ltd. $ROIVSeptember 29, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from AnalystsSeptember 27, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeptember 25, 2025 | seekingalpha.comRoivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 24, 2025 | seekingalpha.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 416,182 Shares of StockSeptember 24, 2025 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 SharesSeptember 23, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 611,000 SharesSeptember 23, 2025 | marketbeat.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 683,818 Shares of StockSeptember 23, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call TranscriptSeptember 23, 2025 | seekingalpha.comBrokers Issue Forecasts for ROIV Q1 EarningsSeptember 22, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for ROIV EarningsSeptember 22, 2025 | marketbeat.comMatthew Gline Purchases 3,315 Shares of Roivant Sciences (NASDAQ:ROIV) StockSeptember 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $24.00September 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $20.00 Price Target at JPMorgan Chase & Co.September 19, 2025 | marketbeat.comGuggenheim Increases Roivant Sciences (NASDAQ:ROIV) Price Target to $21.00September 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $22.00 at Leerink PartnersSeptember 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $16.50 Price Target at Bank of AmericaSeptember 19, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock PriceSeptember 19, 2025 | marketbeat.comMatthew Gline Acquires 3,315 Shares of Roivant Sciences (NASDAQ:ROIV) StockSeptember 19, 2025 | insidertrades.com29,982 Shares in Roivant Sciences Ltd. $ROIV Purchased by Inspire Investing LLCSeptember 19, 2025 | marketbeat.comRoivant Sciences price target raised to $20 from $18 at JefferiesSeptember 18, 2025 | msn.comRoivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive ResultsSeptember 18, 2025 | insidermonkey.comRoivant Sciences (NASDAQ:ROIV) Hits New 1-Year High - What's Next?September 18, 2025 | marketbeat.comRoivant: Brepocitinib's DM Data Impress, Pipeline Focus NarrowsSeptember 18, 2025 | seekingalpha.comRoivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune DiseaseSeptember 17, 2025 | msn.comRoivant Sciences Ltd. (ROIV) Discusses on Brepocitinib in DM: VALOR Phase 3 Study Results ConferenceSeptember 17, 2025 | seekingalpha.comRoivant Sciences Ltd. (ROIV) Discusses On Brepocitinib In DM: VALOR Phase 3 Study Results Conference (Transcript)September 17, 2025 | seekingalpha.comRoivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease TrialSeptember 17, 2025 | benzinga.comS&P 500 Futures Steady in Premarket Trading; Workday, Roivant Sciences LeadSeptember 17, 2025 | barrons.comRoivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune DiseaseSeptember 17, 2025 | msn.comRoivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trialSeptember 17, 2025 | reuters.com Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ROIV Media Mentions By Week ROIV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROIV News Sentiment▼0.250.47▲Average Medical News Sentiment ROIV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROIV Articles This Week▼138▲ROIV Articles Average Week Get the Latest News and Ratings for ROIV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Roivant Sciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TAK News Today ONC News Today INSM News Today BNTX News Today TEVA News Today GMAB News Today SMMT News Today ASND News Today RDY News Today VTRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ROIV) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ROIV Stock Alerts